Ask AI
ProCE Banner Activity

Risposte alle domande chiave sul trattamento ottimale per i pazienti con leucemia linfatica cronica recidivata/refrattaria

Clinical Thought

In questa attività, gli esperti affronteranno le questioni chiave nella cura dei pazienti con leucemia linfatica cronica (CLL) recidivata/refrattaria (R/R), in base alla discussione tenutasi in un precedente webinar dal vivo. Queste risposte serviranno a fornire informazioni concrete e applicabili, che gli operatori sanitari coinvolti potranno utilizzare nella loro attività clinica.

Released: December 23, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Faculty Disclosure

Primary Author

Othman Al-Sawaf, MD

Department of Hematology and Oncology
University Hospital of Cologne
Cologne, Germany

Othman Al-Sawaf, MD: consultant/advisor/speaker: AbbVie, Adaptive, AstraZeneca, BeiGene, Gilead, Janssen, Lilly, Roche; researcher: AbbVie, BeiGene, Janssen, Roche.

Farrukh T. Awan, MD, MS, MBA

Professor of Internal Medicine
Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapies
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Farrukh T. Awan, MD, MS, MBA: consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Bristol Myers Squibb, Dava Oncology, Genmab, Incyte, Invivyd, Loxo Oncology, Miltenyi, Pierre Fabre; data and safety monitoring board: Ascentage, AstraZeneca, Caribou Biosciences.

Alessandra Tedeschi, MD

Medical Doctor
Department of Hematology
Niguarda Cancer Center Milano
Milano, Italy

Alessandra Tedeschi, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Johnson & Johnson.